Germany does not intend to conclude the discussions in the EU Council on the draft regulation on health technology assessments (HTA). However, it is continuing its work in a working group. A new meeting is scheduled for 1 September.
The proposed Regulation introduces “common clinical assessments” to determine the added value of a medicinal product or of certain of the most innovative in vitro medical devices, with a view to assisting Member States in making pricing and reimbursement...